AR119339A1 - DERIVADOS DE TIOFENO[3,2-b]PIRIDINA COMO INHIBIDORES DE eIF4E - Google Patents

DERIVADOS DE TIOFENO[3,2-b]PIRIDINA COMO INHIBIDORES DE eIF4E

Info

Publication number
AR119339A1
AR119339A1 ARP200101877A ARP200101877A AR119339A1 AR 119339 A1 AR119339 A1 AR 119339A1 AR P200101877 A ARP200101877 A AR P200101877A AR P200101877 A ARP200101877 A AR P200101877A AR 119339 A1 AR119339 A1 AR 119339A1
Authority
AR
Argentina
Prior art keywords
pyridine derivatives
thiophene
eif4e
inhibitors
alkyl
Prior art date
Application number
ARP200101877A
Other languages
English (en)
Spanish (es)
Inventor
Samuel Sperry
Alan X Xiang
Justin T Ernest
Siegfried H Reich
Paul A Sprengeler
Mike Shaghafi
Theo Michels
Christian Nilewski
Chinh Viet Tran
Garrick Kenneth PACKARD
Alan Grubbs
Kaveri Urkalan
Takasuke Mukaiyama
Original Assignee
Effector Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effector Therapeutics Inc filed Critical Effector Therapeutics Inc
Publication of AR119339A1 publication Critical patent/AR119339A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP200101877A 2019-07-02 2020-07-02 DERIVADOS DE TIOFENO[3,2-b]PIRIDINA COMO INHIBIDORES DE eIF4E AR119339A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962869662P 2019-07-02 2019-07-02

Publications (1)

Publication Number Publication Date
AR119339A1 true AR119339A1 (es) 2021-12-09

Family

ID=71614984

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101877A AR119339A1 (es) 2019-07-02 2020-07-02 DERIVADOS DE TIOFENO[3,2-b]PIRIDINA COMO INHIBIDORES DE eIF4E

Country Status (15)

Country Link
US (2) US11286268B1 (https=)
EP (1) EP3994139A1 (https=)
JP (1) JP7595055B2 (https=)
KR (1) KR20220061945A (https=)
CN (1) CN114269756B (https=)
AR (1) AR119339A1 (https=)
AU (1) AU2020299362B2 (https=)
BR (1) BR112021026682A2 (https=)
CA (2) CA3085255A1 (https=)
CL (1) CL2021003573A1 (https=)
IL (1) IL289456A (https=)
PY (1) PY2031844A (https=)
TW (1) TWI748541B (https=)
UY (1) UY38773A (https=)
WO (1) WO2021003157A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220378821A1 (en) * 2019-07-02 2022-12-01 Effector Therapeutics, Inc. Methods of treating braf-mutated cancer cells
EP4076438A4 (en) * 2019-12-18 2023-11-29 Merck Sharp & Dohme LLC BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HERPES VIRUSES
WO2021240337A1 (en) * 2020-05-27 2021-12-02 Effector Therapeutics, Inc. Covalent modifiers of eif4e inhibiting compounds
JP2023554521A (ja) 2020-12-22 2023-12-27 ファイザー・インク Eif4e阻害剤の固体形態
JP2025539263A (ja) * 2022-11-10 2025-12-04 リボメトリックス,インコーポレイティド eIF4E阻害剤としての化合物及び組成物、ならびにそれらの使用
TW202428278A (zh) * 2022-12-23 2024-07-16 大陸商南京聖和藥業股份有限公司 作為eIF4E抑制劑的化合物及其應用
IL326137A (en) 2023-07-28 2026-03-01 Cogent Biosciences Inc PI3K inhibitors
WO2025101516A1 (en) * 2023-11-06 2025-05-15 Ribometrix, Inc. Methods of using eif4e inhibitors for treating cancer
WO2025120599A1 (en) * 2023-12-08 2025-06-12 Ribometrix, Inc. METHODS OF USING eIF4E INHIBITORS FOR TREATING CANCER

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20110065671A1 (en) * 2008-05-19 2011-03-17 Harris Joel M Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2014179237A1 (en) 2013-04-29 2014-11-06 Vanderbilt University Substituted 3-benzylquinoxalin-4(3h)-one analogs as positive allosteric modulators of muscarinic acetycholine receptor m1
WO2015120350A2 (en) 2014-02-07 2015-08-13 Effector Therapeutics, Inc. Compositions and methods for treating fibrotic disease
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 MnK抑制劑及其相關方法

Also Published As

Publication number Publication date
CN114269756A (zh) 2022-04-01
CA3188446A1 (en) 2021-01-07
AU2020299362A1 (en) 2022-02-24
PY2031844A (es) 2021-04-19
TWI748541B (zh) 2021-12-01
JP7595055B2 (ja) 2024-12-05
CA3085255A1 (en) 2021-01-02
WO2021003157A1 (en) 2021-01-07
IL289456A (en) 2022-02-01
JP2022539256A (ja) 2022-09-07
KR20220061945A (ko) 2022-05-13
UY38773A (es) 2021-01-29
BR112021026682A2 (pt) 2022-03-15
CL2021003573A1 (es) 2022-08-12
US11286268B1 (en) 2022-03-29
TW202115058A (zh) 2021-04-16
CN114269756B (zh) 2024-05-14
EP3994139A1 (en) 2022-05-11
US20230108594A1 (en) 2023-04-06
AU2020299362B2 (en) 2026-02-26

Similar Documents

Publication Publication Date Title
AR119339A1 (es) DERIVADOS DE TIOFENO[3,2-b]PIRIDINA COMO INHIBIDORES DE eIF4E
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
NZ766835A (en) Pharmaceutical compounds
MX2019010736A (es) Inhibidor del antigeno de superficie del virus de la hepatitis b.
PE20221504A1 (es) Derivados de un inhibidor de fgfr
MX2019008698A (es) Derivado de piridina como inhibidor de ask1 y metodo de preparacion y uso del mismo.
GEAP202215475A (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
PH12020500485A1 (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
GEAP202215535A (en) Compounds
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
AR096758A1 (es) Inhibidores cristalinos de bromodominios
CL2023001369A1 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CL2022003045A1 (es) Quimioterápicos de éter macrocíclico heteroaromático solicitudes relacionadas
EP4420732A3 (en) Fused ring heteroaryl compounds and their use as trk inhibitors
MX2022006608A (es) Nuevos inhibidores de aurora cinasa y uso de los mismos.
GEAP201914679A (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX381994B (es) Inhibidor de janus quinasa.
TN2017000374A1 (en) TGF-β INHIBITORS
ZA202007566B (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
MY182884A (en) Pyrazole-amide compound and medicinal uses therefor
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
CL2019001694A1 (es) Compuestos de pirazolopirimidina y métodos de uso de los mismos.
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
CO2019003894A2 (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia

Legal Events

Date Code Title Description
FA Abandonment or withdrawal